Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression (Q38553935)

4 September 2017

1 reference

title

Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression (English)

1 reference

4 September 2017

0 references

1 reference

Elise Schutte

1

1 reference

4 September 2017

Ron T Gansevoort

2

1 reference

4 September 2017

Jacqueline Benner

3

1 reference

4 September 2017

Helen L Lutgers

4

1 reference

4 September 2017

Hiddo J Lambers Heerspink

5

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 August 2015

1 reference

Nephrology Dialysis Transplantation

4 September 2017

1 reference

4 September 2017

30 Suppl 4

1 reference

4 September 2017

iv96-104

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

4 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Antihypertensive therapy in the presence of proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Microalbuminuria: a parameter that has changed diabetes care

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Use and misuse of the receiver operating characteristic curve in risk prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Interpreting incremental value of markers added to risk prediction models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Towards better clinical prediction models: seven steps for development and an ABCD for validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

Developing risk prediction models for kidney injury and assessing incremental value for novel biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV119

21 January 2018

Identifiers

DOI

10.1093/NDT/GFV119

1 reference

4 September 2017

1 reference